31
Pascal Sebastian Bailon, Arthur Campfield, Rene Devos, Yves Guisez: Pegylated obese (ob) protein compositions. Hoffmann La Roche, George W Johnson, William H Epstein, Lewis J Kreisler, February 15, 2000: US06025324 (5 worldwide citation)

Polyethylene and polypropylene protein conjugates which modulate body weight of ani is and humans for the treatment, prevention and control obesity and associated diseases or conditions, and the recombinant expression of these biologically active proteins in purified and homogeneous forms.


32
Kirvin L Hodge, Shalini Sharma, Albert C Lee, Reid W von Borstel: Compounds for the treatment of metabolic disorders. Wellstat Therapeutics Corporation, Lewis J Kreisler, November 10, 2009: US07615575 (4 worldwide citation)

Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, artherosclerosis and arteriosclerosis are disclosed. Formula (I) wherein n is 1 or 2; m is 0, 1, 2, 4 or 5; q is 0 or 1; t is 0 or 1; ...


33
Shalini Sharma, Reid W von Borstel, Kirvin L Hodge, Michael K Bamat, Stephen D Wolpe: Method for the treatment of metabolic disorders. Wellstat Therapeutics Corporation, Lewis J Kreisler, December 14, 2010: US07851494 (4 worldwide citation)

Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.


34
Gottfried Alber, Peter Angehrn: Compositions of G-CSF and TNF-BP for prophylaxis and treatment of septic shock. Hoffman La Roche, George W Johnston, William H Epstein, Lewis J Kreisler, July 7, 1998: US05776895 (4 worldwide citation)

The present invention is directed to products containing G-CSF and a TNF binding protein and compositions of G-CSF and TNF-BP, and methods of treating and/or preventing septic shock by administering the products and compositions of the invention.


35
Franz Bauer, Lawrence F Courtney: Cyclohexanediol derivatives. Hoffmann La Roche, George E Johnston, William H Epstein, Lewis J Kreisler, October 19, 1999: US05969190 (4 worldwide citation)

The compound, (E)-(1R,3R)-5-[(R)-11-hydroxy-7,11-dimethyl-dodec-2-enylidene]-cyclohexane -1,3-diol of the formula I: ##STR1## is useful in the treatment or prevention of hyperproliferative skin diseases, particularly psoriasis, basal cell carcinomas, disorders of keratinization and keratosis; or for ...


36
Joachim Veits: Process for producing 2-keto-L-gulonic acid esters. Roche Vitamins, George W Johnston, William H Epstein, Lewis J Kreisler, April 28, 1998: US05744634 (4 worldwide citation)

A process for the manufacture of methyl or ethyl 2-keto-L-gulonate by esterifying 2-keto-L-gulonic acid with methanol or ethanol continuously in the presence of an acidic ion exchanger in the temperature range between room temperature and about 80.degree. C. and with average residence times between ...


37
Shalini Sharma: Compounds for the treatment of metabolic disorders. Wellstat Therapeutics Corporation, Lewis J Kreisler, January 4, 2011: US07863475 (3 worldwide citation)

Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.


38
Kirvin L Hodge, Shalini Sharma, Albert C Lee, Reid W von Borstel: Method for the treatment of metabolic disorders. Wellstat Biologics Corporation, Lewis J Kreisler, April 26, 2011: US07932290 (3 worldwide citation)

Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. wherein n is 1 or 2; m is 0, 1, 2, 4, or 5; q is 0 or 1; t is 0 or 1; R2 is alkyl ...


39
Kirvin L Hodge, Shalini Sharma, Reid W von Borstel, Stephen D Wolpe: Treatment of metabolic disorders. Wellstat Therapeutics Corporation, Lewis J Kreisler, January 12, 2010: US07645772 (3 worldwide citation)

Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.


40
John C Bell, Brian D Lichty, David F Stojdl: Mutant vesicular stomatitis viruses and uses thereof. Ottawa Hospital Research Institute, Wellstat Biologics Corporation, Douglas A Golightly, Lewis J Kreisler, June 8, 2010: US07731974 (3 worldwide citation)

The present invention provides mutant viruses with a decreased ability to block nuclear transport of mRNA or protein in an infected cell which are attenuated in vivo. The mutant viruses of the present invention may also be capable of triggering the anti-viral systems of normal host cells while remai ...